Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Vanderbilt-Ingram Cancer Center
Study ID
NCT03932786
Status
Recruiting
Apply to this trial

Conditions

  • Biological Sibling
  • Cancer Survivor
  • Intraocular Retinoblastoma
  • Retinoblastoma
  • Unilateral Retinoblastoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Biospecimen collection — PROCEDURE
    Collection of tissue and saliva samples
  • Vision assessment — OTHER
    Undergo vision assessment
  • Questionnaire administration — OTHER
    Complete questionnaires
  • Quality of life assessment — OTHER
    Complete questionnaires
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies

Study Details

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma

Key Dates

Start date
Jan 24, 2019
Status verified
Sep 2025
Primary completion
Jan 31, 2030
Completion
Jan 31, 2031

Study Design

Enrollment
900 participants (estimated)

Arms

  • Arm: Retrospective(biospecimens, vision assessment, questionnaires)
  • Arm: Prospective (biospecimens, vision assessment, questionnaires)

Primary Outcome Measure

Incidence of acute toxicity [ Time Frame: Up to 1 year ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Lurie Children's HospitalChicagoIllinois60611
Monica Newmark
[email protected]
Joanna Weinstein, MD (PRINCIPAL_INVESTIGATOR)
University of Illinois, ChicagoChicagoIllinois60612
Kristen kitsch
[email protected]
Mary Lou Schmidt, MD (PRINCIPAL_INVESTIGATOR)
University of MinnesoaMinneapolisMinnesota55455
Kendra Pallin
[email protected]
Joseph Neglia, MD (PRINCIPAL_INVESTIGATOR)
Washington School of Medicine at St. LouisSt LouisMissouri63110
Kara Sauerburger
[email protected]
Robert Hayashi, MD (PRINCIPAL_INVESTIGATOR)
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229
Amanda Pfeiffer
[email protected]
Rajaram Nagarajan, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Stephen Markham
[email protected]
Amish Shah, MD, PhD (PRINCIPAL_INVESTIGATOR)
Vanderbilt-Ingram Cancer CenterNashvilleTennessee37232
Vanderbilt-Ingram Service for Timely Access
800-811-8480
MD Anderson Cancer CenterHoustonTexas77030
Theresa Honey
[email protected]
Anna Herzog, MD (PRINCIPAL_INVESTIGATOR)
Texas Childeren's HospitalHoustonTexas77030
Murali Chintagumpala, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital of WisconsinMilwaukeeWisconsin53226
Veronica Seher
[email protected]
Cindy Schwartz, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
Lurie Children's Hospital· Chicago, ILUniversity of Illinois, Chicago· Chicago, ILUniversity of Minnesoa· Minneapolis, MNWashington School of Medicine at St. Louis· St Louis, MOCincinnati Children's Hospital Medical Center· Cincinnati, OHChildren's Hospital of Philadelphia· Philadelphia, PA

Related Studies